Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

6.9K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.9K
Mismatch Repair01:36

Mismatch Repair

44.5K
Overview
44.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

17.5K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teaching at scale: a mixed-methods study of team-based learning analytics to enable early support in medical education.

BMC medical education·2026
Same author

Androgen receptor and fatty acid oxidation cooperate in ferroptosis evasion in BRAFi resistant melanoma.

Cell death & disease·2026
Same author

Using Theater Gaming to Foster Perspective-Taking and Mitigate Bias Among Trauma Providers.

Journal of trauma nursing : the official journal of the Society of Trauma Nurses·2025
Same author

Perioperative management of antihypertensive agents.

Minerva medica·2025
Same author

Development, validation, and clinical assessment of a liquid chromatography-tandem mass spectrometry serum assay for per- and polyfluoroalkyl substances (PFAS) recommended by the National Academies of Science, Engineering, and Medicine (NASEM).

Analytical and bioanalytical chemistry·2024
Same author

Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells.

Pharmaceutics·2024

Related Experiment Video

Updated: Mar 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance.

Michael P Smith1, Claudia Wellbrock2

  • 1Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 1, 2016
PubMed
Summary

Targeting the MAPK pathway with cancer drugs like BRAF and MEK inhibitors shows initial promise but leads to drug resistance. Understanding nonmutational drug tolerance is key to developing better combination therapies.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Related Experiment Videos

Last Updated: Mar 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Targeting the mitogen-activated protein kinase (MAPK) signaling pathway is a validated cancer treatment strategy.
  • BRAF and MEK inhibitors (e.g., vemurafenib, trametinib) induce tumor regression but responses are often transient, leading to inevitable drug resistance.
  • Tumor heterogeneity and the emergence of resistant clones present significant challenges for salvage therapies.

Purpose of the Study:

  • To discuss the early dynamics of inhibitor response during tumor regression.
  • To explore the mechanisms of nonmutational drug tolerance in cancer.
  • To identify strategies for overcoming drug resistance in MAPK-targeted therapies.

Main Methods:

  • Review of current literature on MAPK pathway inhibition and drug resistance.
  • Discussion of adaptive cellular rewiring, including negative feedback loops, gene expression changes, and intracellular signaling adaptation.
  • Analysis of the role of the tumor microenvironment and external signaling in promoting drug tolerance.

Main Results:

  • MAPK pathway inhibition triggers adaptive rewiring, involving relief of negative feedback, gene expression changes, and altered signaling.
  • Nonmutational drug tolerance can be mediated by the tumor microenvironment and selection for inherently tolerant cells.
  • Preclinical combination strategies using RTK inhibitors, HDAC inhibitors, or specific agents like nelfinavir show potential in overcoming early drug tolerance.

Conclusions:

  • Understanding the mechanisms of nonmutational drug tolerance is crucial for improving cancer treatment outcomes.
  • Combination therapies targeting both MAPK signaling and adaptive resistance mechanisms may enhance drug sensitivity and prolong remission.
  • Further research into adaptive rewiring and tumor microenvironment interactions is needed to develop effective salvage strategies.